Therefore, optimizing the first-line regimen for treatment of advanced NSCLC patients negative for driver genes, addressing the challenges of resistance to immunotherapy plus chemotherapy and optimizing the treatment strategies for EGFR-mutated NSCLC patients following resistance to targeted therapy, remain to be addressed in clinical practices (13). Here, EGFR is linked to non-small cell lung carcinoma.